This company listing is no longer active
Acasti Pharma Croissance future
Future contrôle des critères 4/6
Informations clés
-28.1%
Taux de croissance des bénéfices
-30.2%
Taux de croissance du BPA
| Pharmaceuticals croissance des bénéfices | 54.5% |
| Taux de croissance des recettes | 26.1% |
| Rendement futur des capitaux propres | n/a |
| Couverture par les analystes | Low |
| Dernière mise à jour | 16 Feb 2023 |
Mises à jour récentes de la croissance future
Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 3/31/2025 | 97 | -38 | 27 | N/A | 3 |
| 3/31/2024 | 160 | 161 | 12 | -25 | 2 |
| 3/31/2023 | N/A | -6 | -17 | -17 | 2 |
| 12/31/2022 | N/A | -17 | -16 | -16 | N/A |
| 9/30/2022 | N/A | -17 | -17 | -17 | N/A |
| 6/30/2022 | N/A | -11 | -19 | -19 | N/A |
| 3/31/2022 | N/A | -10 | -17 | -17 | N/A |
| 12/31/2021 | 0 | -12 | -16 | -16 | N/A |
| 9/30/2021 | 0 | -11 | -15 | -15 | N/A |
| 6/30/2021 | 0 | -18 | -14 | -14 | N/A |
| 3/31/2021 | 0 | -20 | -14 | -14 | N/A |
| 12/31/2020 | 0 | 3 | -16 | -15 | N/A |
| 9/30/2020 | N/A | -6 | -19 | -18 | N/A |
| 6/30/2020 | N/A | -21 | -21 | -20 | N/A |
| 3/31/2020 | N/A | -26 | -23 | -23 | N/A |
| 12/31/2019 | N/A | -56 | -29 | -29 | N/A |
| 9/30/2019 | N/A | -46 | -29 | -29 | N/A |
| 6/30/2019 | N/A | -42 | -27 | -27 | N/A |
| 3/31/2019 | N/A | -39 | -25 | -25 | N/A |
| 12/31/2018 | N/A | -31 | -20 | -19 | N/A |
| 9/30/2018 | N/A | -34 | -17 | -16 | N/A |
| 6/30/2018 | N/A | -20 | -13 | -13 | N/A |
| 3/31/2018 | N/A | -17 | -10 | -10 | N/A |
| 3/31/2017 | N/A | -8 | -7 | -5 | N/A |
| 11/30/2016 | 0 | -7 | N/A | -5 | N/A |
| 8/31/2016 | 0 | -7 | N/A | -5 | N/A |
| 5/31/2016 | 0 | -6 | N/A | -6 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: ACST's earnings are forecast to decline over the next 3 years (-28.1% per year).
Bénéfices vs marché: ACST is forecast to become profitable over the next 3 years, which is considered above average market growth.
Croissance élevée des bénéfices: ACST is expected to become profitable in the next 3 years.
Chiffre d'affaires vs marché: ACST's revenue (26.1% per year) is forecast to grow faster than the Canadian market (5.5% per year).
Croissance élevée des revenus: ACST's revenue (26.1% per year) is forecast to grow faster than 20% per year.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Insufficient data to determine if ACST's Return on Equity is forecast to be high in 3 years time